Introduction {#sec1_1}
============

Radiation recall describes a well-known, but poorly understood phenomenon by which administration of chemotherapy or another systemic agent induces an inflammatory reaction within a previously irradiated field \[[@B1]\]. Radiation recall was first described in 1959, when it was found that latent effects of radiation, such as dermatitis, could be induced by actinomycin D \[[@B2]\]. Though clinically rare, since that time radiation recall has been observed for various other systemic agents and inciting factors \[[@B3]\]. While the recall phenomenon is most commonly reported as dermatitis, it has also been observed in other organs including the lung, intestine, and muscles \[[@B1], [@B4], [@B5], [@B6]\]. Gemcitabine has previously been implicated in radiation recall. When reported, it is noted to preferentially affect internal tissue and organs \[[@B7]\]. Herein we report a case of a 39-year-old woman with myositis that is clinically consistent with gemcitabine-induced radiation recall (GIRR) myositis. We also review reported cases of GIRR myositis and discuss the findings and implications.

Case Description {#sec1_2}
================

Events are outlined in the timeline (Fig. [1](#F1){ref-type="fig"}) and summarized below. In 2008, the 39-year-old patient was diagnosed with metastatic ER-negative, PR-negative, HER2-positive cancer. At initial presentation, PET scan demonstrated both regional lymph node involvement and osseous metastases. She was started on systemic therapy with Adriamycin and Cytoxan, followed by Taxol and Herceptin. Subsequent therapies included maintenance single-agent Herceptin, followed by Herceptin and lapatinib. By late 2011, her osseous disease showed complete radiologic response on PET scan, and she was offered local therapy to the primary tumor. In January 2012, she underwent a right mastectomy, with ypT2N1a disease, followed by postmastectomy radiation up to 50 Gy with a 10-Gy chest wall boost.

In late August 2012, she presented with a painful osseous lesion at the T12 vertebra and an impending pathologic fracture of the left distal femur. She underwent surgical stabilization of the femur with rod placement, followed by postoperative radiotherapy, 30 Gy in 10 fractions (Fig. [2a](#F2){ref-type="fig"}). T12 was treated with single-fraction stereotactic body radiotherapy (SBRT) up to 24 Gy.

In December 2012, gemcitabine (1,000 mg/m^2^, days 1 and 8) and Herceptin were given in a 21-day cycle. In January 2013, she presented to the Emergency Department with leg swelling, shortness of breath, and pleuritic chest pain to the lower thorax. Physical examination noted left leg swelling and some mild effusion of the left knee. The ultrasound was negative for deep vein thrombosis (DVT), and the chest CT was negative for pulmonary embolism. Symptoms were attributed to a viral syndrome with associated pleurisy.

The patient\'s symptoms had worsened at the time of her reexamination by oncology on March 2013. PET scan showed increased FDG activity and edema in the left thigh that was thought to be consistent with postradiation inflammatory changes (Fig. [2b](#F2){ref-type="fig"}). MRI of the thoracic spine demonstrated paraspinal muscle fluid collections and a new T12 fracture, and chemotherapy was held. CT-guided biopsy of the paraspinal fluid collection was negative for abscess or malignancy. Although a T12 vertebroplasty improved the chest/back pain and her swelling, her leg pain persisted.

On March 19, 2013, gemcitabine and Herceptin were resumed with a 20% gemcitabine dose reduction. Within 2 days, she developed worsening leg pain and swelling, and required the use of a cane for ambulation. Repeat extremity ultrasound showed no evidence of DVT, but revealed marked, diffuse enlargement of the vastus medialis or rectus femoris muscles of the left thigh, suggestive of myositis. At that time, her providers noted that her symptoms appeared and worsened following each gemcitabine administration, but improved off chemotherapy. Given the temporal relationship and other negative evaluation, the patient\'s symptoms were attributed to GIRR from the prior palliative radiotherapy to the left femur. Gemcitabine was stopped, and she was started on dexamethasone and physical therapy. The patient required dexamethasone for relief of her symptoms until August 2013. After a slow taper, she regained leg function and was not rechallenged with gemcitabine.

Over the subsequent 3 years, she had received treatment with Herceptin, ado-trastuzumab, and eribulin/Herceptin without recurrence of the symptoms. Gait was described as normal at the most recent follow-up, and she was described as physically active, engaging in regular exercise. In retrospect, it is also possible that the exacerbation of pain and fluid collection within the paraspinal muscles of T12 seen in March of 2013 may have been related to recall myositis in that region.

Literature Review {#sec1_3}
=================

A literature search was performed using the search terms "gemcitabine," "radiation," "recall," and "myositis" to compile known reports of GIRR myositis (Table [1](#T1){ref-type="table"}, Table [2](#T2){ref-type="table"}, Table [3](#T3){ref-type="table"}). Twenty-one cases were identified as having myositis in a radiation port following gemcitabine treatment. Fractionated radiation doses ranged from 28 to 70.2 Gy.

The time interval between radiation and chemotherapy initiation ranged from 0 days to 4 months. The majority had chemotherapy more than 1 month after radiotherapy. The time between radiation and onset of recall symptoms varied from 4 weeks to 5.5 months. Only 1 patient had symptoms less than 1 month after radiation, 20 were ≥3 months, 10 were ≥4 months, and 7 were ≥5 months. All patients achieved at least partial improvement of their symptoms with discontinuation of gemcitabine, regardless of whether their treatment consisted of steroids (9 patients), NSAIDs (5 patients), analgesics (4 patients), or no treatment at all (2 patients). Out of the 9 confirmed patients who resumed chemotherapy following myositis, 5 patients underwent gemcitabine rechallenge, with only 1 patient requiring concomitant steroids for symptom control.

The patient described in the present report is consistent with other reported cases. The time intervals between chemotherapy, radiotherapy, and the onset of symptoms are within the range of the other cases. The current case of possible myositis at T12 was the only case associated with a single fraction of ablative radiotherapy. Interestingly, our patient had prior chest wall radiotherapy, but did not develop evidence of recall in that location. In review of the literature, this is consistent with other cases in which recall myositis did not appear in all prior sites of radiotherapy. Remote courses were less often affected by recall myositis. These findings are also consistent with prior reviews of radiation recall that suggest a possible relationship between the time interval from radiation to chemotherapy and the severity of recall symptoms \[[@B1], [@B3], [@B8]\]. However, such a correlation likely depends on the relationship between several factors, such as drug type, dosage, radiation location, radiation dosage, and timing of each treatment \[[@B3]\].

Discussion {#sec1_4}
==========

Radiation recall is a delayed inflammatory response at a site of prior radiation \[[@B9], [@B10]\]. GIRR has been noted to have a predilection for soft tissue and internal organs, resulting in a less typical appearance of radiation recall. For example, GIRR has been documented to cause pseudocellulitis, acute ascending colitis, abdominal wall and subcutaneous fat stranding, optic neuritis, lymphangitis, rectal hemorrhage, brainstem radionecrosis, and myositis \[[@B5], [@B9], [@B11], [@B12], [@B13]\]. These atypical presentations highlight the importance of clinical awareness of GIRR.

The diagnosis of GIRR myositis is challenging, as it may appear similar to infection, thrombosis, or other sources of inflammation \[[@B14]\]. A few key signs may help distinguish this condition. Primarily, the inflammation is confined to a prior radiation portal. Furthermore, there is a temporal relationship between the timing of gemcitabine administration and appearance of symptoms \[[@B9]\]. Radiologic studies may be used to support the diagnosis of myositis with appearance of swelling and edema of the underlying musculature. They may also assist in ruling out other potential etiologies \[[@B15]\]. Because reported cases of myositis have been associated with elevated creatinine kinase and even compartment syndrome, appropriate recognition and treatment is essential to facilitate recovery and minimize morbidity \[[@B10], [@B16], [@B17]\]. Review of cases suggests that the most important factor for resolution is the discontinuation of gemcitabine, with the potential use of anti-inflammatory medications.

The mechanisms of action of radiation recall remain poorly understood. However, the varied presentations of GIRR, even within an individual\'s prior sites of radiotherapy, suggest that multiple factors influence both the appearance and severity of recall. Jeter et al. \[[@B11]\] proposed that the doses of gemcitabine of 600 mg/m^2^ or higher may pose a higher recall risk. Others suggest that higher radiation treatment doses or shorter intervals between radiotherapy and chemotherapy may influence recall development \[[@B9]\]. However, these are not well-defined risk factors. With an increased use of gemcitabine across many tumor types, along with routine use of definitive and palliative radiotherapy, clinicians should be alerted to this possible complication.

We suspect that the exacerbation of pain at the site of T12 SBRT along with the MRI and biopsy findings are consistent with a focal recall myositis at that location. Our patient did not have further exacerbation of pain at that site with the dose-reduced gemcitabine. This suggests that the intervention with vertebroplasty may have affected the local environment. The underlying recall mechanism may also have differed from that in the leg. Radiation recall at an SBRT-treated site had been reported in the past, although the recall effect was induced by sorafenib and manifested itself in the form of dermatitis \[[@B18]\].

Due to its rare and unpredictable onset, radiation recall continues to be a poorly understood phenomenon. This is further complicated by the possibility that there are multiple mechanisms for different medications (gemcitabine, carboplatin, etc.) and/or types of recall (dermatitis, myositis, etc.). Current hypotheses for explaining radiation recall include sensitivity of descendants of cells that survive radiation, changes in local vasculature, and drug-induced hypersensitivity reactions \[[@B1]\]. There is not enough evidence to support any definite mechanism \[[@B1], [@B9]\]. However, the drug-induced hypersensitivity hypothesis appears to best explain the characteristics of radiation recall. This hypothesis describes radiation recall as a nonimmune inflammatory reaction triggered by certain drugs at a site where the inflammatory threshold has been lowered by radiation. Prior radiation to a specific site may induce constant low-level expression of several inflammatory cytokines, including IL-1, IL-6, PGDF-β, TNF-α, and TGF- β \[[@B18]\]. Introduction of drugs such as gemcitabine may then lead to upregulation of such inflammatory cytokines inducing the recall reaction \[[@B1]\]. This theory is further supported by the various clinical presentations of radiation recall, including the timing of onset, the lack of worsening reactions following rechallenge in some cases, and the induction of recall from noncytotoxic agents (such as simvastatin) \[[@B1], [@B8]\].

Conclusion {#sec1_5}
==========

In conclusion, GIRR myositis is a rare, but significant reaction that may present like other conditions such as DVT or infection. As such, it should be part of the differential diagnosis when a patient on gemcitabine reports pain and swelling to a previously irradiated area, although other causes should be thoroughly investigated. In particular, GIRR myositis should be considered when there is a shorter time interval between the completion of radiation and the initiation of chemotherapy. Discontinuation of chemotherapy and possibly the use of anti-inflammatory medications are important steps to reduce symptoms and improve the patient\'s quality of life. In some cases, patients have been successfully rechallenged with gemcitabine, although that may not always be possible.

Statement of Ethics {#sec1_6}
===================

The authors have no ethical conflicts to disclose. IRB approval was obtained.

Disclosure Statement {#sec1_7}
====================

The authors declare that there is no conflict of interest.
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![Top left: radiation fields of the left femur, with sagittal (top left), coronal (top right), and axial (bottom) views. The isodose levels shown are 16.7, 50, 95, and 100%. Top right: PET/CT showing edema and increased FDG uptake of the left thigh, consistent with myositis, with front-facing 3D (top) and axial (bottom) views. Bottom: MRI showing edema of the left thigh, consistent with myositis, with T1-weighted coronal images (top left), T2-weighted coronal images (top right), and T1-weighted axial images (bottom).](cro-0011-0168-g02){#F2}

###### 

Collection of previous case reports of gemcitabine-induced radiation recall myositis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                      Cancer type                  Radiation location                               Dose                                                            CTx regimen                                                                                                                                                                               Time between RT and gemcitabine start                 Time between RT completion and recall symptoms   Clinical symptoms/signs                                                                            Under-going chemo at time of symptom onset?   Imaging findings (and modality)                                                                                           Treatment                                                                                                                      Outcome                                                                                                                                         Post-treatment CTx?
  --------------------------- ---------------------------- ------------------------------------------------ --------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------ -------------------------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------
  Alco et al. \[[@B19]\]      Pancreatic adeno carcinoma   Pancreas and regional lymph nodes                1.8 Gy × 25 (45 Gy)                                             Gemcitabine 1,250 mg/m^2^/week, 3 weeks in 4 week cycle                                                                                                                                   0 (concurrent)                                        20 weeks                                         Tender mass, pain, and swelling of abdominal muscles                                               No (last dose 1 month before onset)           Edema and inflammation of the anterior and right abdominal wall muscles (MRI)                                             Corticosteroids, NSAIDs, and gabapentin                                                                                        Symptom reduction in 1 week; clinical and radiologic findings resolved in 1 month                                                               N/A

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Alco et al. \[[@B19]\]      NSCLC                        Left upper lobe and ipsilateral L2 lymph nodes   62 Gy total (fractions N/A)                                     Gemcitabine (1,200 m/m^2^ for 1--8 days), and carboplatin (AUC 5.5 for days 1 and 30), for 3 cycles; gemcitabine reduced to 800 mg/m^2^ after first cycle because of intolerance          N/A (CTx started after RT)                            N/A (∼104 days after starting CTx)               Pain and swelling of left breast and chest wall, with reduced ROM of arm and shoulder              No (last dose 2 weeks before onset)           Edema and soft tissue reaction at the left breast musculature and subcutaneous soft tissue (MRI)                          Corticosteroids, NSAIDs, opioids, antihistamines, SOD, pentoxifylline, vitamin E, gabapentin, topical lidocaine and selenium   Meds did not affect myositis; pain reduced after 4 months, resolved after 9 months, with lasting reduced ROM                                    N/A

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Delavan et al. \[[@B15]\]   Breast cancer                Left thigh                                       8 Gy × 1 (8 Gy)\                                                Gemcitabine (unknown dosage)                                                                                                                                                              17 days                                               107 days                                         Increasing pain and swelling to the posterior left thigh, warm to palpation                        No (last dose ∼3.5 weeks before onset)        Increased signal intensity in the posterior thigh musculature (MRI)                                                       Dexamethasone                                                                                                                  Symptoms improved over 3 days, symptom free 1 week later                                                                                        Not reported
                                                                                                            (4 years prior)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                            3 Gy × 13 (39 Gy)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                            (4 months prior)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Eckardt et al. \[[@B17]\]   Synovial sarcoma             Right forearm                                    3.5 Gy × 8 (28 Gy) preop, followed by 2 Gy × 10 (20 Gy) boost   Gemcitabine (900 mg/m^2^ on days 1 and 8) and docetaxel (100 mg/m^2^ on day 8) for 2 cycles at 21 and 28 days, respectively                                                               5 days                                                40 days                                          Swelling of the right forearm with progressively worsening range of motion, compartment syndrome   No (last dose 7 days before onset)            Edema of the flexor compartment muscles, with layering fluid along the superficial fascia and between the muscles (MRI)   Dexamethasone                                                                                                                  Patient required slow taper corticosteroids for multiple months; patient continues to have muscle edema and myositis on 1-year follow-up MRI.   No

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Fakih \[[@B20]\]            Pancreatic adenocarcinoma    Pancreas                                         1.8 Gy × 28 (50.4 Gy)                                           Concurrent fluorouracil (2,000 mg/m^2^/day for 5 days a week) and gemcitabine (200 mg/m^2^ weekly) followed by adjuvant gemcitabine (1,000 mg/m^2^/week for 3 weeks every 4-week cycle)   0 days (concurrent)\                                  ∼18 weeks                                        Erythematosus rash overlying a tender mass in the epigastrium                                      Yes                                           Enlarged left and right rectus abdominus with areas of heterogeneity (CT)                                                 None, other than withholding gemcitabine                                                                                       Complete resolution                                                                                                                             Yes (capecitabine, docetaxel, and cisplatin)
                                                                                                                                                                                                                                                                                                                                                                      ∼21 days to initiation of adjuvant dose gemcitabine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Fogarty et al. \[[@B21]\]   NSCLC                        Lung                                             3 Gy × 12 (36 Gy)                                               Gemcitabine (1,000 mg/m^2^ on days 1 and 8) and carboplatin (AUC 5, day 1)                                                                                                                ∼3 months                                             ∼4.5 months                                      Posterior chest wall pain with localized tenderness, skin rash, elevated CK, ESR                   Yes                                           Enhancement of the chest wall musculature consistent with nonspecific inflammatory change (MRI)                           NSAIDS, oral steroids                                                                                                          Symptoms improved but persistent minor skin changes and subcutaneous fibrosis                                                                   Not reported
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Collection of previous case reports of gemcitabine-induced radiation recall myositis (continued)

  Author                                                     Cancer type                                                   Radiation location                  Dose                     CTx regimen                                                                                                                              Time between RT and gemcitabine start   Time between RT completion and recall symptoms   Clinical symptoms/signs                                                          Undergoing chemo at time of symptom onset?   Imaging findings (and modality)                                                                                                                       Treatment                             Outcome                                                     Post-treatment CTx?
  ---------------------------------------------------------- ------------------------------------------------------------- ----------------------------------- ------------------------ ---------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- ------------------------------------------------ -------------------------------------------------------------------------------- -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- ----------------------------------------------------------- --------------------------------------------------
  Friedlander et al. \[[@B7]\]                               Pancreatic adenocarcinoma                                     Pancreas and regional lymph nodes   1.8 Gy × 28 (50.4 Gy)    Gemcitabine (40 mg/m^2^ biweekly and concurrently with radiation, followed by 1,000 mg/m^2^ weekly for 3 weeks per month)                39 days                                 3 months                                         Tenderness of rectus muscles, mild rash, elevated CK                             Yes                                          Increased signal in the subcutaneous tissue of the anterior abdominal wall (MRI)                                                                      Corticosteroids                       Complete resolution, no recurrence after steroid tapering   Not reported
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Ganem et al. \[[@B22]\]                                    Squamous cell carcinoma of the lung                           Pelvis                              3 Gy × 11 (33 Gy)        Gemcitabine (1,000 mg/m^2^ on days 1, 8, 15) and cisplatin (100 mg/m^2^ on day 15)                                                       1.5 months                              5 months                                         Right buttock pain                                                               Yes                                          Hypersignal and edema on gluteal soft tissue (MRI)                                                                                                    Oral opiates, antibiotics, steroids   Alleviation over the course of 3 months                     Not reported
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Graf et al. \[[@B16]\]                                     NSCLC and anal cancer, history of dermatomyositis             Pelvis                              Not reported             5-FU and MMC given with pelvic RT for anal cancer, carboplatin and gemcitabine (dosage not given)                                        2 months                                4 months                                         Erythema, swelling, warmth, and tenderness of the buttocks and groin area        Yes                                          High signal in the bilateral gluteal maximus, quadratus femoris, adductor magnus, obturator externus and right iliopsoas muscles (MRI), elevated CK   Prednisone and opiate analgesia       Gradual improvement with steroids                           Not reported
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Grover et al. \[[@B5]\]                                    Adenocarcinoma and neuroendocrine neoplasm, unknown primary   Left hip and left acromion          3 Gy × 10 (30 Gy)        Gemcitabine (1,250 mg/m^2^) and carboplatin (AUC 5)                                                                                      2 weeks                                 4 weeks                                          Worsening pain in left shoulder and hip                                          Yes                                          Soft tissue edema of the muscles adjacent to the left acromion and the left hip (MRI)                                                                 Narcotics                             Pain resolved 5 months after radiotherapy                   Gemcitabine therapy continued
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Horan et al. \[[@B23]\]                                    NSCLC                                                         Lung                                3 Gy × 8 (24 Gy)         Gemcitabine (1,000 mg/m^2^, weekly)                                                                                                      2 months                                ∼13 weeks                                        Pain and swelling of the right pectoralis major, biopsy proven muscle necrosis   Yes                                          Thickening of right pectoralis major muscle (CT)                                                                                                      Analgesics                            Symptoms gradually declined when gemcitabine was stopped    Gemcitabine re-challenge, no further symptoms
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Jeter et al. \[[@B11]\]                                    Pancreatic adenocarcinoma                                     Pancreas                            1.8 Gy × 28 (50.4 Gy)    Gemcitabine (1,000 mg/m^2^ one dose; followed by 750 mg/m^2^ weekly for 9 months)                                                        3 weeks                                 3 months                                         Abdominal wall tenderness and erythema                                           Yes                                          Subcutaneous fat stranding and decreased density of rectus muscles in radiation portal (CT)                                                           Ibuprofen                             Symptoms responsive to ibuprofen                            Gemcitabine re-challenge, no further symptoms
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Lock et al. \[[@B24]\]                                     Hepatic adenocarcinoma                                        Liver                               2.94 Gy × 15 (44.1 Gy)   Gemcitabine (1,000 mg/m^2^ for days 1 and 8 for a 3-week cycle)                                                                          8 weeks                                 18 weeks                                         Abdominal discomfort with induration; overlying skin erythema                    Yes                                          Enhancement of abdominal muscles with thickening (MRI)                                                                                                Ibuprofen, vitamin E, and vitamin C   Gradual resolution over the course of 6 weeks               Gemcitabine was continued, reduction of symptoms
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Miura et al. \[[@B25]\][^a^](#T3F1){ref-type="table-fn"}   NSCLC                                                         Right hip                           2 Gy × 25 (50 Gy)        Concurrent cisplatin (80 mg/m^2^ day 1) and vinorelbine (20 mg/m^2^, days 1, 8, and 15) followed by gemcitabine (800 mg/m^2^ biweekly)   1 month                                 3 months                                         Right thigh pain                                                                 N/A                                          Edema within right thigh muscles (MRI)                                                                                                                Analgesics                            Gradual resolution of symptoms                              Yes (unknown regimen)

###### 

Collection of previous case reports of gemcitabine-induced radiation recall myositis (continued)

  Author                                                      Cancer type                Radiation location                             Dose                                  CTx regimen                                                                                                                                                                   Time between RT and gemcitabine start   Time between RT completion and recall symptoms   Clinical symptoms/signs                                                         Undergoing chemo at time of symptom onset?     Imaging findings (and modality)                                                                                Treatment                          Outcome                                                                                                                              Post-treatment CTx?
  ----------------------------------------------------------- -------------------------- ---------------------------------------------- ------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- ------------------------------------------------ ------------------------------------------------------------------------------- ---------------------------------------------- -------------------------------------------------------------------------------------------------------------- ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------
  Miura et al. \[[@B25]\][^a^](#T3F1){ref-type="table-fn"}    NSCLC                      Lung                                           2 Gy × 30 (60 Gy)                     Concurrent cisplatin and (80 mg/m^2^ day 1) and vinorelbine (20 mg/m^2^, days 1 and 8) followed by vinorelbine (13 mg/m^2^ biweekly) and gemcitabine (800 mg/m^2^ biweekly)   3 months                                5.5 months                                       Upper chest muscle pain                                                         N/A                                            Enhancement of pectoralis muscles (MRI)                                                                        NSAIDs                             Improvement of symptoms                                                                                                              Yes (gefitinib)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  O\'Regan et al. \[[@B10]\]                                  Hodgkin lymphoma           Chest                                          1.8 Gy × 22 (39.6 Gy)                 4 cycles of gemcitabine, vinorelbine, and liposomal doxorubicin (unknown dosage)                                                                                              2 months                                5 months                                         Worsening bilateral anterior chest pain, pectoralis muscle necrosis by biopsy   No (last dose 2.5 weeks before presentation)   Diffuse bilateral swelling of the pectoral muscles with mild stranding of the adjacent subcutaneous fat (CT)   Analgesics                         Complete resolution                                                                                                                  Not reported
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Patel et al. \[[@B26]\]                                     Nasopharyngeal carcinoma   Head and neck                                  70.2 Gy total (fractions N/A)         Gemcitabine (1,000 mg/m^2^) and oxaliplatin (100 mg/m^2^) every 2 weeks                                                                                                       N/A (CTx started after RT)              6 months                                         Bilateral neck pain and swelling with restriction of neck movement              Yes                                            Diffuse bilateral soft-tissue edema of the muscles in the cervical neck (MRI)                                  Dexamethasone                      Symptoms worsened with tapering of dexamethasone/low-dose prednisone started without recurrence.                                     Not reported
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Pinson et al. \[[@B27]\][^b^](#T3F2){ref-type="table-fn"}   NSCLC                      Lung                                           3 Gy × 10 (30 Gy)                     Carboplatin (AUC 5 on day 1) and gemcitabine (1,000 mg/m^2^ on days 1 and 8), 3-week cycle                                                                                    4 weeks                                 14 weeks                                         Skin erythema, upper chest muscle pain                                          Yes                                            Swelling of the pectoralis major and pectoralis minor (CT)                                                     Ibuprofen                          Complete resolution in 3 weeks                                                                                                       Not reported
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Squire et al. \[[@B14]\]                                    NSCLC                      Pelvis (left sacroiliac and left acetabulum)   3 Gy × 10 (30 Gy)                     Gemcitabine (1,000 mg/m^2^)                                                                                                                                                   1 month                                 3 months                                         Tenderness and discomfort to left hip and buttock, elevated CK                  Yes                                            Edema in gluteal muscles (MRI)                                                                                 Oral prednisone                    Symptoms worsened with tapering of prednisone and improved with increasing doses                                                     Gemcitabine continued for 5 more months, symptoms controlled with prednisone
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Welsh et al. \[[@B28]\]                                     Bladder cancer             Para-sacral region                             2.5 Gy × 18 (45 Gy)                   Gemcitabine and cisplatin (unknown dosage)                                                                                                                                    4 weeks                                 5 months                                         Pain in bilateral superolateral gluteal regions                                 Yes                                            Band-like pattern of edema on gluteal region (MRI)                                                             NSAIDs, prednisone                 Complete resolution after 6 weeks, but with visible residual scar and muscular atrophy                                               CTx continued
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Current                                                     Breast cancer              Left thigh (femur)/T12 vertebra                3 Gy × 10 (30 Gy)/24 Gy × 1 (24 Gy)   Gemcitabine (1,000 mg/m^2^ for days 1 and 8) and herceptin (342 mg every 3 weeks)                                                                                             54 days/79 days                         3 months/5.7 months                              Worsening leg pain and swelling/Chest and back pain                             Yes                                            Enlargement of muscles of the left thigh (US)/ T12 fracture and paraspinal fluid collections (MRI)             Dexamethasone/T12 vertebroplasty   Progressive resolution of symptoms after 4-month course of dexamethasone/Reduction of chest and back pain following vertebroplasty   Yes (herceptin)
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